|
26 Companies |
|
33 Products |
|
33 Products |
|
27 Mechanisms of Action |
|
0 Trials |
|
159 News |
|
| «123 |
- |||| PF 4634817 / Pfizer
Enrollment open: A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy (clinicaltrials.gov) - Feb 12, 2013
P2, N=176, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting
- pioglitazone / Generic mfg., nitroglycerin / Generic mfg.
Trial termination: Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function (clinicaltrials.gov) - Jan 31, 2013
P=N/A, N=36, Terminated, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Completed --> Terminated; Low enrollment because of the specifics of the inclusion criteria
- pioglitazone / Generic mfg., nitroglycerin / Generic mfg.
Enrollment change: Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function (clinicaltrials.gov) - Jan 31, 2013
P=N/A, N=36, Terminated, Sponsor: Mayo Clinic
Completed --> Terminated; Low enrollment because of the specifics of the inclusion criteria N=60 --> 36
- Enrollment change: Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial (clinicaltrials.gov) - Jan 6, 2013
P=N/A, N=35, Active, not recruiting, Sponsor: University of Michigan
N=60 --> 36 N=75 --> 35
- Enrollment closed: Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial (clinicaltrials.gov) - Jan 6, 2013
P=N/A, N=35, Active, not recruiting, Sponsor: University of Michigan
N=75 --> 35 Recruiting --> Active, not recruiting
- | Kuvan (sapropterin) / BioMarin, Daiichi Sankyo
Enrollment closed: Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria (clinicaltrials.gov) - Jan 6, 2013
P2, N=40, Active, not recruiting, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- ||||| apararenone (MT-3995) / Mitsubishi Tanabe
New P2 trial: A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR (clinicaltrials.gov) - Dec 25, 2012
P2, N=90, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||||| apararenone (MT-3995) / Mitsubishi Tanabe
New P2 trial: A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria (clinicaltrials.gov) - Dec 25, 2012
P2, N=90, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Tekturna (aliskiren) / PDL
Biomarker, Trial termination: ARIA: To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (clinicaltrials.gov) - Dec 20, 2012
P2, N=8, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; In consequence of termination of ALTITUDE. A number of studies were continued in consultation with the Altitude Data Monitoring Committee.
- Tekturna (aliskiren) / PDL
Biomarker, Enrollment change: ARIA: To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (clinicaltrials.gov) - Dec 20, 2012
P2, N=8, Terminated, Sponsor: Novartis Pharmaceuticals
A number of studies were continued in consultation with the Altitude Data Monitoring Committee. N=32 --> 8
- PF 3882845 / Pfizer
Trial termination: A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy (clinicaltrials.gov) - Dec 4, 2012
P1, N=6, Terminated, Sponsor: Pfizer
N=32 --> 8 Recruiting --> Terminated; See termination reason in detailed description.
- Tekturna (aliskiren) / PDL
Trial termination: Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients (clinicaltrials.gov) - Nov 5, 2012
P4, N=2, Terminated, Sponsor: John H. Stroger Hospital
Recruiting --> Terminated; See termination reason in detailed description. Suspended --> Terminated; Altitude trial which used similar drugs was terminated due to increased ADR.
- Tekturna (aliskiren) / PDL
Enrollment change: Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients (clinicaltrials.gov) - Nov 5, 2012
P4, N=2, Terminated, Sponsor: John H. Stroger Hospital
Suspended --> Terminated; Altitude trial which used similar drugs was terminated due to increased ADR. N=30 --> 2
- |||| Xinlay (atrasentan) / Novartis
Trial completion: Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor (clinicaltrials.gov) - Oct 24, 2012
P2, N=149, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=30 --> 2 Active, not recruiting --> Completed
- ||||| PF 4634817 / Pfizer
New P2 trial: A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy (clinicaltrials.gov) - Oct 21, 2012
P2, N=176, Recruiting, Sponsor: Pfizer
- || paricalcitol / Generic mfg.
New P3 trial: Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria (clinicaltrials.gov) - Sep 25, 2012
P3, N=70, Not yet recruiting, Sponsor: Oslo University Hospital
- |||| Xinlay (atrasentan) / Novartis
Trial completion: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan (clinicaltrials.gov) - Sep 11, 2012
P2, N=58, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| paricalcitol / Generic mfg.
Trial initiation date: Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients (clinicaltrials.gov) - Sep 4, 2012
P3, N=166, Recruiting, Sponsor: University Medical Centre Ljubljana
Active, not recruiting --> Completed Initiation date: Dec 2011 --> Jul 2012
- |||||| paricalcitol / Generic mfg.
Enrollment open: Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients (clinicaltrials.gov) - Sep 4, 2012
P3, N=166, Recruiting, Sponsor: University Medical Centre Ljubljana
Initiation date: Dec 2011 --> Jul 2012 Not yet recruiting --> Recruiting
- | ABT-614 / AbbVie
Trial completion: A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine. (clinicaltrials.gov) - Aug 20, 2012
P1, N=16, Completed, Sponsor: Abbott
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| INV-144 / InVasc Therap
Trial completion: INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria (clinicaltrials.gov) - Aug 4, 2012
P2, N=88, Completed, Sponsor: InVasc Therapeutics, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: CKD/ESRD-MIT: Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD (clinicaltrials.gov) - Jun 7, 2012
P=N/A, N=120, Recruiting, Sponsor: Providence Medical Research Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Enrollment open: Effect of CSII and CGM on Progression of Late Diabetic Complications (clinicaltrials.gov) - Jun 5, 2012
P4, N=80, Recruiting, Sponsor: Steen Andersen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: RCP-MM: Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=50, Recruiting, Sponsor: Rennes University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- eplerenone / Generic mfg.
Enrollment change: Eplerenone, ACE Inhibition and Albuminuria (clinicaltrials.gov) - May 24, 2012
P2, N=30, Completed, Sponsor: Radboud University
Not yet recruiting --> Recruiting N=72 --> 30
- eplerenone / Generic mfg.
Trial completion: Eplerenone, ACE Inhibition and Albuminuria (clinicaltrials.gov) - May 24, 2012
P2, N=30, Completed, Sponsor: Radboud University
N=72 --> 30 Recruiting --> Completed
- ||| valsartan / Generic mfg.
Enrollment change: To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - May 5, 2012
P4, N=509, Completed, Sponsor: Novartis
Recruiting --> Completed N=700 --> 509
- |||| valsartan / Generic mfg.
Trial completion: To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - May 5, 2012
P4, N=509, Completed, Sponsor: Novartis
N=700 --> 509 Active, not recruiting --> Completed
- | New P4 trial: ESPECIAL: Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan (clinicaltrials.gov) - Mar 11, 2012
P4, N=270, Recruiting, Sponsor: Seoul National University Bundang Hospital
- ||||| emapticap pegol (NOX E36) / TME Pharma
New P2a trial: NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria (clinicaltrials.gov) - Mar 6, 2012
P2a, N=76, Completed, Sponsor: NOXXON Pharma AG
- PF 3882845 / Pfizer
New P1 trial: A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy (clinicaltrials.gov) - Dec 6, 2011
P1, N=6, Terminated, Sponsor: Pfizer
- valsartan / Generic mfg., lisinopril / Generic mfg.
Enrollment change: Antialbuminuric Effects of Valsartan and Lisinopril (clinicaltrials.gov) - Nov 6, 2011
P4, N=54, Terminated, Sponsor: Novartis
Active, not recruiting --> Completed N=201 --> 54
- ||| valsartan / Generic mfg.
Enrollment change: A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure (clinicaltrials.gov) - Nov 6, 2011
P4, N=109, Completed, Sponsor: Novartis
N=201 --> 54 N=140 --> 109
- Tekturna (aliskiren) / PDL
Enrollment open: Shiga Microalbuminuria Reduction Trial-2 (clinicaltrials.gov) - Nov 2, 2011
P4, N=320, Recruiting, Sponsor: Shiga University
N=140 --> 109 Not yet recruiting --> Recruiting
- | ABT-614 / AbbVie
New P1 trial: A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine. (clinicaltrials.gov) - Nov 1, 2011
P1, N=16, Completed, Sponsor: Abbott
- | Tekturna (aliskiren) / PDL
New P4 trial: Shiga Microalbuminuria Reduction Trial-2 (clinicaltrials.gov) - Oct 26, 2011
P4, N=320, Recruiting, Sponsor: Shiga University
- ||||| New P4 trial: Effect of CSII and CGM on Progression of Late Diabetic Complications (clinicaltrials.gov) - Oct 16, 2011
P4, N=80, Recruiting, Sponsor: Steen Andersen
- | CCX140 / Amgen
New P2 trial: A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria (clinicaltrials.gov) - Sep 22, 2011
P2, N=20, Active, not recruiting, Sponsor: ChemoCentryx
- |||||||||| paricalcitol / Generic mfg.
New P3 trial: Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients (clinicaltrials.gov) - Sep 18, 2011
P3, N=166, Recruiting, Sponsor: University Medical Centre Ljubljana
- ||||| Xinlay (atrasentan) / Novartis
New P2 trial: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan (clinicaltrials.gov) - Aug 25, 2011
P2, N=58, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- Trial termination: RACE II: Rhubarb and Angiotensin Converting Enzyme Inhibitor (clinicaltrials.gov) - Aug 17, 2011
P=N/A, N=8, Terminated, Sponsor: Wake Forest School of Medicine
Not yet recruiting --> Recruiting Recruiting --> Terminated; unable to meet recruitment goal
- Enrollment change: RACE II: Rhubarb and Angiotensin Converting Enzyme Inhibitor (clinicaltrials.gov) - Aug 17, 2011
P=N/A, N=8, Terminated, Sponsor: Wake Forest School of Medicine
Recruiting --> Terminated; unable to meet recruitment goal N=60 --> 8